TCR2 Therapeutics   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03907852
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

TCR2 Therapeutics